Main Products/ Services/ Pipelines & Platforms
AnBogen is a clinical-stage biotech company developing small molecule drugs to address the unmet need in cancer.
Pipeline: ABT-101 • Best-in-class, oral, tyrosine kinase inhibitor targeting HER2 mutations in multiple solid tumor cancers. • Superior safety, PK/PD demonstrated in phase 1 • Phase 2 study will planned in 2024
ABT-301 • Best-in-class, pan-HDAC inhibitor for IO combination to treat solid tumors • Superior anti-tumor activities when combined with PD-1/PD-L1 inhibitors in pre-clinical model • Strongly modulates tumor microenvironment • Phase 1b trial of ABT-301/IO combo is planned in 2024
Business Interests
▪ Out-licensing ▪ Collaborative R&D
Contact Info
Angus Wu
VP, Business Development
+886-2-8979-8616
angus.wu@anbogen.com